AMGN - Earnings call transcript Q4 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

My name is Ian and I will be you conference facilitator today for Amgen's Fourth 2019 Financial Results Conference Call. [Operator Instructions]

I would now like introduce Arvind Sood, Vice President of Investor Relations. Mr.

Sood, you may now begin.

Arvind Sood

Okay. Ian. you, Thank everybody. Good afternoon joining us for today. Thanks

special So progress get to on was us XX for be anniversary. the celebrate gift revenue as steps important year significant made well milestone a surely will celebrate we What that what in our our back position XXXX we and that XXXX year to strategy this better took and to than growth.

Bob Bradway, will the Chairman our and CEO, So, discussion lead today.

Peter XXXX Griffith, today update joined are guidance CFO, a for our We for will by financial who new on QX also provide and and XXXX. results our full year provide

pipeline of Global Head Head then by Gordon, will our review a our of R&D, Our who update. Operations, performance Reese, followed Commercial product Dave Murdo provide will

slides today have discussion use will and our guide the received to should separately. link you We

will and presentation statements. in use some be non-GAAP of We financial forward-looking measures will statements today's also the

factors differ results, subsequent our that Our cause filings XX-K materially. identify and could to results, actual

that, I So the to would over turn with Bob? Bob. like to call

Bob Bradway

good Arvind for you our Thank joining you, thank and . afternoon everyone call Okay. and

portfolio we year, feel exceeded financial XXXX, made patients encouraged our of targets. and serve medicines. XXXX. the of advanced strategy we we of the growing this the for and and more we're around into Heading feeling a new with by again, Once elements key in we progress challenges met past year ready We our our long-term growth world

and evidenced growth to faced fact return many line managed competition. in we we was by our XXXX I we year, products as in top XXXX. earnings long growth that transition for the transition new the well, XXXX delivered this of preparing will had off-patent legacy been as believe

over this us in that the initiatives we for actually and challenge, past In In re-positioned of anticipation the several first well. XXXX, embedded are overall company's productivity the serving time the base years since XXXX. expense drug fell prices U.S.

medicines Prolia, Repatha, to for portfolio volume reshaped recently than like most addition, primarily through and we rather product that increases Aimovig, us growth Evenity, can Products In committing our Otezla. deliver increases. price

we albeit XX% the X% XXXX, small region, seeing United in Asia-Pacific from delivered In growth growth globally especially a volume strong States. our base. outside volume performance We're and

decade, region to account growth. Over expect XX% much we of next as the as this for Amgen's

full the grew from the For came of Over our growth Astellas in XXXX, joint in with venture year world's volume the region in that Japan, pharmaceutical XX%. market. third-largest two-thirds

first enabling that subsidiary Amgen to reminder wholly-owned Just this April Xst, through do a to for on time. a the fully collaboration us in Japan, reverts business

with Our excited weeks achieve two closed strategic in together can market. our few the collaboration China pharmaceutical BeiGene second a ago by world's we're in largest companies and what

for was on on to us, are important and believe also and a business. we several can an biosimilars we growth XXXX time for us our be first for market innings time. watershed biosimilars the our in over early opportunity delivered We've what year budget of

biosimilar our Through later Avsola, will the already Remicade. $X with our business annualizing portfolio we over the billion and year the to launch was of add at this end QX, to of

other that Otezla. Europe We expect acquisition recent parts in also biosimilar Amgevita, our of world Humira to from the benefit and will our of

be intend and serious that older, continues best-in-class market growth urban wealthier, large mean or pillar world strategy to less. patients trends our deliver for The first-in-class growing to will world more leader these illnesses. biopharmaceutical suffering from and key innovation, bringing We that that size innovation. A the mega more be of delivering a medicines and not effect need to a is

We expect pipeline several XXXX. important data readouts in our from

heart for Otezla in in allergic psoriasis. GXXC and KRAS non-allergic and for data and omecamtiv mild-to-moderate expect inhibitor for We or failure tezepelumab asthma AMG look XXX for

Dave and our we'd BiTE some this as generate Reese will all shortly. In on to across data important in details expect provide addition, well portfolio of XXXX

year, Last how who targets of excited large capabilities number identify and while most our strengthening and pursue through our enabling is scale stand human the adding new genetics research, our expanded from approach to commitment a remain discovery well. to them. collaborations about We world-leading us to proteomic we also benefit data as patients

biotechnology pay breakthroughs. see same patients. company seeing and industry individuals in for we optimistic these be diseases, the who in know our time, we next the to incredible that to and struggling make age we're feel living reason an more to that and breakthrough more At for Everything the across us continues we're how Across governments with are about of innovation.

is to part be them. and advancing market-based to to year, in innovative providing to election to it. that responsibility an patients In about be for really accept with discussion matters solution, the health to that get there innovation both stakeholders forward of access care We ways and medicines in look to other solutions innovative we engaging bound much and promotes promote affordable access

the need addressing social, we stakeholder sustain biotechnology exists part of to ecosystem that governance matters and concern other recognize so be the help in our today. to are process a U.S., constructive be to Just for and of need in the we that recognize to communities accept robust the that innovation as environmental, do we of

lower targets earlier that the a set at To those we are generation to targets now a much manufacturing by traditional a These will year to we biologics that this have developing cost manufacturing later planned, further goals environmental our next years footprint enable water include XXXX. too. than will share smaller next than end, and goals commitment which reducing operate several hit technologies, a year. and year us ago, a set our for consumption emissions Having of XXXX, in we carbon

call our Peter to new CFO, Griffith. let Now, over turn me the

us in and details over in October, to for the you. outlook that XXXX. take will our Peter our recall joined through and XXXX You'll you he performance of Peter,

Peter Griffith

Thanks Bob.

want to saying many as David Amgen on an of take also as am I me join exciting who a to thank, have into I transition the begin team, the time at the role. moment XX-year me by you company's to Let the well how history. call Amgen helped in happy Meline, such

our many members to as and continued months, of the Over enjoyed the forward the as engagement. community investors last several dialog look I and analyst meeting well I've of

turn decreased let's we $X.X the deck. fourth Revenues with year-over-year declines substantially at products worldwide product offset launch in on the declined saw by X% our quarter, to billion X slide and portfolio financial to quarter. the the in growth our results mature Page our products. quarter X% as of Now, fourth transition sales $X.X billion In

into also benefit collaboration which our as expansion month. with which encouraged particularly closed are from which by markets, We earlier ex-U.S. gives XX% we China, confidence BeiGene, will the our volume driven our global growth including us from strong this continue

basis. impact had X% Other exchange sales Foreign negative up QX revenues a fourth at were million on million $XXX XXXX. versus a quarter year-over-year $XX worldwide to

compared Non-GAAP Our prior XX.X% quarter, QX at non-GAAP margin for X% decreased operating the year. operating XX.X% QX income was of from $X.X XXXX. in to billion

As previously which quarter expenses underlining and in fourth pattern, pipeline additional operating investment rapidly closed our indicated, oncology the operating reflected evolving portfolio - in expenses increased the our Otezla acquisition, typical QX. with underlying associated

$XX Other year-over-year across from continued favorable expenses offset all a million QX, were of net and expense expense favorability. million our initiatives productivity impacts $XXX income partially in representing increases by operating were categories. expense These

traded transaction This our partially and fluctuations lower balances. from market to of to and driven portfolio, publicly held due gains interest by offset venture's value securities generated favorability liquidating investments favorable bond income reduced fund was in BeiGene cash by the Otezla

was with count in benefit for The a associated billion XXXX. year-over-year increased tax QX $X.X the reduction versus point one-time non-GAAP X.X reform. share was tax earnings income to X% XX.X% primarily due a versus non-GAAP fourth prior-year U.S. quarter, by a tax under per for increase intercompany the rate quarter, corporate QX supported net and XXXX, Non-GAAP X% share sales

Next, results on presentation. I X full-year will review of our Page the XXXX,

X% non-GAAP share to decreased $XX.X XXXX, Our per while per our billion, full-year revenues to earnings $XX.XX share. X% grew

X% we revenues in $XX the year, the product $X.X year-over-year. were billion. Volume billion at Other year-over-year. to worldwide For sales full $XX.X markets outside growth decline million was XX% a in down U.S. saw

our In the prior operating for was year non-GAAP income down and in decreased full the total, at billion $XX.X year, the non-GAAP margin X% XX.X% For operating non-GAAP XXXX. from from year, XX.X% operating billion. Otezla by launch our our year-over-year to of productivity the to offset product support, program. and expenses was addition Development growth and Research by partially This investments, business, driven $XX.X increased X%

cash a Otezla Other on income expenses million XXXX reduced year-over-year balances. primarily and offset income due from to BeiGene interest lower and from by the gains in basis partially fund by $XXX favorable were bonds resulting to transactions, liquidating

U.S. the non-GAAP one-time a to tax XXXX. sales rate for X.X benefit with intercompany reforms. Again, primarily XX% corporate versus associated points was tax full year, The tax due prior-year under up

X. Page in balance Turning next on to flow the cash sheet

portfolio The diversified driven continued For to billion versus the flow advance cash with in Free structure. strong of industry-leading coupled of deposit. $X.X and flow, decline lower a full cost an timing XXXX, cash billion $XX.X generate products Amgen income, tax working in capital, an XXXX. net was XXXX reflecting by year

returned and at per of followed used shares in billion $XXX dividend $XX.X an billion this $X.X we $XX.X billion repurchase the XXXX. XXXX, $XX.X $X.X capital to of of a to In totaling billion shareholders return shareholders payments total share. million through to average And

offset cash of decrease partially cash and from All XX billion rate form at return average by years. Debt the dividends driven by weighted totaled was flow outstanding carries totaled interest decrease generated maturity end This and average investments Cash shareholders the free XXXX, of X.X% repayment. period. primarily a the a transaction, end share $XX.X XXXX. Otezla debt $X.X as well as of and billion billion with $XX.X at an repurchases the during of year-end of of to in the

to XXXX new as the of on generate for out Now global business business innovative in will differentiated molecules XXXX build we X. year important and for the growth be support for our the and the outlook and turning another to to the continue Amgen, page products. pipeline invest

previously of enable opportunity on net a a to prices, and position strength. this in pressure developed us we As continued fully of downward discussed to from invest capability productivity anticipation

to to per guidance Otezla $XX.XX due our per earnings share related of share share the revenue guidance earnings $XX.X from per share, to to $XX.XX is per EPS, $XX.XX acquisition. share. amortization non-GAAP divergence per share intangibles XXXX billion is which and to $XX.X our GAAP billion non-GAAP primarily $XX.XX Our guidance is per

year, friendly capital $XXX Rhode in tax Island. including this XX.X% XX.X% non-GAAP and of once generation expenditures our expect leading is approximately million facility industry next manufacturing guidance again, environmentally Our rate we to

Let me guidance. embedded assumptions key our several mention in

continued Aimovig, portfolio. franchises, range increasing against filgrastim Repatha, First, our our strong revenue time, same as products and ESA worldwide Prolia, as including Sensipar. from biosimilar well expect reflects growth Otezla we competition our the and Evenity, guidance At

experienced net Next, selling regard decline a to XXXX. prices, we in X% with globally

low to digit globally. middle experienced to XXXX, expect again single declines we For

We the net more offset declines. expect than our volume growth to price

business base on be our Overall, expect basis. stable in year-over-year to XXXX excluding as previously stated, Otezla, we a

you the model that in the quarter revenue note quarter historically of the first year. XXXX, As represents sales product lowest

As we in for similar a look will should percent the quarter in explain remarks. QX sales the of of saw year, the full to further XXXX. first percentage Murdo product his

XXXX, $X.X in year With against increased we on an respect for year-over-year to portfolio. as revenue, basis. total expense expect royalty operating an percentage full we we grow double-digit billion product XXXX From anticipate other expect operating to perspective, the the low about range our non-GAAP absolute overall expenses competition

three in programs As by received our BeiGene offset innovative new from and to we our pipeline collaboration. following partially the we recoveries increase assumptions. previously communicated, indications invest investment Non-GAAP as Otezla R&D reiterate R&D advancing

modest acquisition to preparation as of Grow Second, for China begin as product our launch investment non-GAAP we globally, and Otezla business in incremental to our as including support expand to SG&A the late-stage continue our well expense Japan. and business, biosimilars of due pipeline. base increase

be of to a sales as Non-GAAP sales cost with percent generally of XXXX. product consistent

current and primarily of as a lower based income to fund as billion expense consensus $X.X expect range is We our driven share other transactions productivity to anticipate BeiGene's and the billion. a a benefit categories We to to be and expense income on net available publicly by of This interest $X.X used expense results XX.X% our program. all cash in estimates. continue BeiGene non-GAAP from result Otezla as well between

be in quarter in one accounting of I BeiGene's and know with accordance share that method results our XXXX. booked will begins XX.X% therefore of in the arrears equity QX,

X, nominal subsidiary. making Amgen for by April the purchase on wholly-owned shares of a Amgen a held company know, will Astellas BioPharma are you XX% Amgen in that fee, Astellas As the XXXX,

we a market. anticipate long-term largest First, let about limited pharmaceutical the the it this we perspective, We financial me look leveraging excited new this resulting bring we are patients this marks from as seek platform impact From a of objectives. transition as to to third further medicines how achievement near-term transition. say to strategic Amgen's in forward financial

actions principles. the continue to to reflect our following regard will with Now, deployment, capital

First, we growth pipeline seek and of expand to long-term our invest medicines business to innovative in will volume to globally. our drive

external business opportunities. will We in also development prudent invest

shareholders committed share, Second, including share as the of to form $X.XX per repurchases. quarter remain first we the returning XX% dividends, growing increase in well or capital of continued as to in the XXXX

We repurchases view will an timing opportunistic continue take the share towards to 'XX. within of

range an of outstanding repurchases $X.X billion authorization of We $X the to and a within $X amount have expect billion. share in billion

And include third, cost development activities. business does our we to capital impact committed Consistent usual optimal our with minimize potential weighted not order to an investment guidance rating. today in remain grade practice, structure average external retain our capital of our maintaining and the to

and XXXX success in we confident we strong another in the of remain Amgen's XXXX for in in results delivered beyond. So summary, and outlook year financial

I financial now turn the will the to call over concludes update. This Murdo.

Murdo Gordon

good Thanks everyone. Peter, and afternoon

reflect few employees product a Amgen has then since On on and years QX greater early transformed to pioneering of our on take of anniversary, that spirit footprint treatment In review detail. geographical the XXXX innovative the portfolio disease. the we and our incorporation, minutes reflect I'll changed XXth XX in Amgen's dramatically.

remains patients every and serve motivates us to single mission it unchanged Our day.

of patients Our on as we enter behalf further accomplishments about confidence future us XXXX in XXXX. give our

and Repatha, our brands we Prolia, for increases. X%. KANJINTI. volume Amgevita, diverse grew full as includes summarize hematology oncology year, portfolio six as Otezla, our proportion XX% as well To portfolio year-over-year The MVASI such the is posted growing XXXX, and and of This volume Evenity, products Aimovig, by

pharmaceutical expansions growth and in Finally, our will second growth China volume for Amgen and in year-over-year our long-term international contributed the Otezla engines nearly our businesses Japan grew collaboration business Notably, revenues fold. X our XXXX. XX% markets third acquisition BeiGene markets. of for our along and accelerate These largest with with in are

prices Now reported grew quarter X% X% declining declined fourth resulting moving X%. Volumes selling to year-over-year, results. year-over-year. in In sales by by QX, net net

addition we stable a Peter for selling As this despite XXXX mentioned, Otezla, expect a projecting for business declines in we of basis. price the continued portfolio net with have on base our outlook revenue growth year and

dosing, increasing growth details, getting driven strong XX% Japan from Recall trends. new by posted Prolia experiences product uptake Now growth year-over-year, given and year seasonal the in the delivered Evenity strong into injection U.S. Prolia driven both a repeat consistent $XX and higher of by rates. rates patient that quarter, volume in twice million fourth

seconds year, a with That's experienced X.X to million Every XX% and worldwide who medicine. fractures due a occur only women osteoporosis. are treated one fracture fracture bone-building every three of

under-penetrated market, receive on women screening, Evenity, we options to and continue these ensuring diagnosis, the we Given postmenopausal to With nature treatment and offer excellent Prolia focus patients. of this treatment. appropriate have

we've new worldwide growing significant have XX% made for taken progress to by to and in continue year-over-year On major year-over-year, as XX% U.S. QX Repatha, was leader improving access we and XX% grew sales steadily affordability and PCSKX be the class year-over-year, the Repatha. improving are in at to growth prescriptions unit brand steps

original improved of can the list patients and simplified prescription access price more rates removed and the plans we We have at commercial co-pay. to and up We affordable a approval percentage Medicare that XX% increased Repatha offering.

Although previous declined stable sequentially. net in the the the price blended year, selling U.S. of price QX Repatha net was relatively in versus

net based with Repatha's price access our selling step to on obtain contracting broader in For we expect thereafter. a XXXX, down in QX stabilization

on a Slide sales while basis, On grew Aimovig grew onto net X%. Now year-over-year XX% volume XX.

estimates comparison Unit QX basis. changes grew As from of a on impacting benefited in a favorable year-over-year X%. volume million the reminder, accounting XXXX $XX quarter-over-quarter

volume have migraine eligible X are more the has we remaining course Aimovig million in Considering the prescribers. who significant treatment, expect XXXX. prescribed and that CGRP been almost market than U.S. are XX,XXX XXX,XXX drive Aimovig patients over there date, patients this potential to for by To of penetrate growth to

share. access in leads lives Aimovig both has of which and CGRP XX% XX% TRx the to exceptional XX% with and over new covered. prescriptions exited Aimovig of prescriptions prescriptions, over a total with paid QX

basis result when slightly XXXX, to year expect to full decline access, XXXX. for year the on a compared net of a As this we broader price full

impact patients, co-pay QX Additionally, expenses lower sales insurance re-verifications, due the quarters plan benefit work as to of greater in through their subsequent changes, has deductibles. and

XX, already year-over-year Parsabiv quarter. by move grew Slide providers while the FMC We'll midsize utilize their Parsabiv Independent on XX% increase which a fourth to patients continue dialysis of majority DaVita and in and for adoption. to calcimimetic

Next onto Otezla.

continue Celgene, that from to will strong With Otezla. joined help have the of growth professionals drive sales we indications potential team dedicated and the new launch for our

prescription continued the momentum During closed, growth. since with XX% year-over-year period acquisition

gives planned years. label double-digit us to combined ability low annual the confidence over geographic at Our and compound with Otezla our growth next efforts, expansion rate seamless grow integration in five

approximately post in the For were million. $XXX closing Otezla weeks five XXXX, sales

of proportionally Otezla quarter approximate first quarterly of over the sales expect in than the years. in lower the the remaining should The for to be number We last year. quarters pattern historical pattern XXXX

Moving a estimates on in in selling declines. Enbrel partially are trends expected accounting volume in and be favorable to sales unit $XX prices, change those million XXXX. X% increases in driven XXXX by year-over-year to by to increased net Volume similar offset

contract due limited XXXX we As less selling terms. price, favorable net in for versus project XXXX benefit to

focus and two includes our the strengthen to in broadly, through complementary psoriasis their psoriatic in broad an and inflammation we see market; products, With our we're biosimilars, positions opportunity portfolio, highly Avsola. arthritis, more increasing targeting Amgevita, our which

and the R&D asset of Our other late-stage in a assets number pipeline. tezepelumab earlier

which is later. biosimilars integrated to highly our with oncology our Now oncology discuss and hematology business, I'll that

of and KYPROLIS, quarter, Vectibix, totaled BLINCYTO, the in billion Nplate, XGEVA, Our XX% six growing brands IMLYGIC $X.X innovative collectively portfolio year-over-year.

XGEVA by Nplate sales. U.S. in driven year-over-year by - by grew portfolio, larger KYPROLIS grew X% some led driven of XX% in U.S. year-over-year brands volume volume growth. volume. grew for year-over-year the XX% this a driven by increase X% in within X% As the QX

in investments R&D innovations. Our have Nplate for two in resulted

a pediatric indications. First, the as presentation This minimize new patients of we is recently for all Nplate's ITP wastage product at product administered support indication, launched presentation mcg in to across also in weight-based help general dosing. will smaller XXX with

and approval in their to October earlier for course opportunity chance of for received remission. Nplate ITP, us in treatment free the Second, the early serve disease patients of the the gives treatment which provides

$XX emergence XXXX mature Now QX not year-over-year brands, declined U.S. QX more a did with from benefited onto a Neulasta decline XX% of of order, in Recall ASP BARDA XX% our U.S. which CMS reflects the competition, biosimilar Neulasta recent repeat XXXX. sales is Coinciding that the in reduction. million the quarters with XX% in that of two in most a ASP QX calculated in arrears. published for mind Bear

On U.S. holding an share XX% an segment XX%. in volume Neulasta of Onpro with long-acting a share retained the of basis QX, exit of exit

services. We customers have along quality broader our demonstrating are Onpro's our that confidence by our in reliability encouraged customer the durability supply, and of with

a face the biosimilar in competitor competitors development. and now other and third We U.S. remain potential

XXXX order not project model, sales we a recall to you do the that quarter, in $XX from for first million Neulasta XXXX. As that BARDA recur benefited QX,

Finally, commitments further and QX in calls XX% we price continue. due a contractual reduction to expect Switching net price XX, sales starting declined with QX XX% lower DaVita, primarily trends XXXX. those which our outside in on for sales EPOGEN the from to declined U.S., selling slide Nephrology, to

Meanwhile, to declined increased by year-over-year XX% volume driven competition. Aranesp lower due

quarter. million launches in the risk U.S., the XX% in in resulted to recall sales year-over-year $XXX in generic at that were there several Regarding Sensipar, XXXX that declining

in significant ex-U.S. supplemental Kingdom, in XXXX. the for a Italy, cinacalcet In United Spain, patent protection expire will in likely result France, sales XXXX, certificates which in decline Germany, and

integrated is the close company. our the throughout product portfolio, innovative with biosimilar I'll which business our section highly with

the a same examples, innovative our these brands. network majority manufacturing were products of as with As made

us chain same distribution. the across identify We biosimilars the in learnings innovative side, we apply leverage to synergies it continue commercial highly our on supply And rapidly allowing efficient commercializing a making and portfolio. alongside selling our our also for products, model to

to now same patient our provider innovative services and expect to increasingly portfolio. These competitors We XXXX. biosimilar and face with KANJINTI also and as other during we competition important enter as the advantages offer MVASI additional are

MVASI biosimilar of portfolio in the U.S. recorded QX the Our U.S. and KANJINTI outside MVASI and and Amgevita, of comprised KANJINTI million. of $XXX sales

very adoption KANJINTI and sales rates and the adoption U.S., in we've accelerating. and hospital recorded the In million MVASI clinic is of seen encouraging each segment $XX

there quarter. the where launch, the Given led also Amgevita. stocking during stage biosimilars some from early Ex-U.S. is million $XXX of by inventory sales our

products important and while price Germany in to and We see of larger strong exhibit and continue terms differences including levels, markets sustainable a markets erosion opportunity. experiencing markets more and at balanced uptake with more uptake pricing France between some discounted other

Here In evolution year our footprint nicely with portfolio was oncology, growth able brands. Otezla drive Amgevita Otezla. our portfolio. our defending leverage of mature now given to including in uptake of and we solid while we're product plan summary, expertise efforts XXXX the our synergized again, of a products, In while to volume XXXX,

turn Let it me over Dave to now Reese.

Dave Reese

afternoon Thanks everyone. Murdo good and

upfront express global to our pipeline to We're enthusiasm the good look advance collaboration. working As are I'd to cardiovascular we inflammation, programs say from therapeutic the but together moment, enter and areas, forward oncology and looking a to clinical three take the XXXX, about our oncology, data molecules. of start we oncology for opportunity a across in disease. our more like to innovative of development forward to important off I'll BeiGene

inflammation. I'll now in quarterly begin review my

may data that a failed needed mild-to-moderate in therapy. topical XXX approved over this provide This population We psoriasis we available much from X are Otezla confident year has expect study treatment that patients Phase patient therapy option. Otezla oral a no and have with

and the We're indication Europe toward of in evaluating in including label scalp FDA studies also Otezla. data year. we're inclusion for are There on this to opportunity for expand the ongoing the pediatric a working the U.S. studies new psoriasis additional with the CHMP with Behcet's indications, psoriasis and

our X TSLP and you severe asthma. year, Phase later this I'll antibody, development data also remind with in tezepelumab that uncontrolled expect AstraZeneca we from

to for the Europe rapidly Evenity osteoporosis approved UCB, new in at of we bone. health, a bone the treatment in is testament pleased approval in the high postmenopausal along that fracture. first women for last of build medicine for osteoporosis with to decade, new In risk were therapy a can the receive need Evenity severe European

development later year forward Turning a monotherapy continue patients rapidly months when to in lung least had monotherapy study pivotal look six potentially this program first-in-class to enrolled AMG our non-small approximately the cell XXX, advanced for oncology inhibitor. We and Phase KRAS X advance hematology, cancer three GXXC in we the that follow-up cancer all previously we X at we data have sharing of months cohort patients. our on I advanced in Phase study. enrolled to and mentioned colorectal

Based have on colorectal as generated assess we have we'll further and potential the path to-date, we enrollment our study data additional development available. to cancer become opened the in data

monotherapy We expect from we our where year information of colon on in types tumors, additional solid other also lung data and data later than cancer. and to will tumor as duration study therapy as present this more well have first-in-human

also in data our cell lung combination X Phase expect We initial from advanced study cancer. with KEYTRUDA non-small

well MEK our non-small We combination in in study lung patients enrolling cancer as our X patients lung non-small treatment-naive cell Phase advanced study. colorectal and inhibitor as cancer ongoing monotherapy are cell

the to progresses. continue primarily as additional We program combination updates studies and provide we'll trials plan

an in about format. in Based We platform and year. we confident emerging enthusiastic extended our hematologic remain in half-life malignancies evidence solid the are activity both on of will increasingly growing BiTE XXXX anti-tumor be tumors, important

cytokine-release syndrome. tumor important different and programs and BiTE we such our As as management we insights dose schedule advance are into gaining adverse of in clinical events settings,

customized target disease depending guide approaches, and development on the underlying will insights These biology.

these and year, the presentations sharing I'll provide of some further expected of data course guidance programs these data anticipate from as we the molecules advance. on Over

now expressed XXX, pursuing directed cancer initiated against half-life BiTE for first-in-human recently and cancer. programs target which gastric in is MUCXX, are We for a a two AMG widely extended gastric study

highly Asia, and is East have growing we Japan know our presence you where subsidiary in impending as BeiGene. through a with cancer, Gastric prevalent collaboration

in extended present this I likely we intend data XXX, As have meaningful AMG to when previously half-life we the second or a year. BCMA of dataset, BiTE for half the discussed, most

in for medicines. to KYPROLIS multiple these oncology, U.S., also in BeiGene working look BLINCYTO CANDOR and several made the dexamethasone AOL. plus regulatory We've China relapse study advance China the with refractory submissions important including We and relapsed-refractory forward to for in KYPROLIS myeloma in

omecamtiv Cytokinetics, we year. data along Phase cardiovascular quarter the X the in fourth disease, In from this the mecarbil to the outcome of forward study look

cardiovascular recent heart expected in we remains in based medical and failure landscape expect to AMG to Phase global of to residual continues significant advance siRNA, the unmet epidemic. XXX we is disease, the on year. from in believe our LP(a) data this drug While the X first change half treatment classes, other initiate need Also development

aflibercept Finally, ABP XXX, Rituxan. for receive study U.S. biosimilar ABP to on our biosimilars, to XXX, for Phase initiating we're our are a with also that Xth submission U.S. pleased X approval and biosimilar Avsola, I'm Remicade make regulatory biosimilar our pleased EYLEA. our announce or our we biosimilar to

Bob?

Bob Bradway

our Okay. don't Thanks, Dave. Ian, the remind please and lines why we process. open the callers of up for questions now

Operator

of from Jay? line Our Co. Oppenheimer first is Olson Instructions] & from Jay question [Operator

Jay Olson

any in You elaborate Aimovig. you. there? you CGRP maybe leverage the little for talked could you expect competitive up dynamic a pricing about shape you the potentially how to and Thank dynamics data, long-term net little a Could on bit bit space

Murdo Gordon

And of a benefit did uptake. CVS, we our a benefit. of do with the we year - XX% and of Aimovig Murdo it's position We're have as market new over very in we've year this also this Aimovig at We're here. not seen CVS now with access covered the Aimovig's as the acceleration having for Jay, very with and a last of pleased patient to access question beginning year already pleased Thanks affordable with co-pay. lives, addition as

We percentage are that happy Aimovig are of the above that receiving XX%. patients paid prescriptions is now of

the and they're a of at have of is migraine future there an eligible that out them, for days on impact, in there able access And category this we've because million patients lot well very the And that U.S. got effective Aimovig growth have a to of bodes impact X we reduction medicines migraine the highly sufferers. significant co-pay. on a affordable

So future of for the the good category. that's outlook

QX because secure reduction to to then and price will there that see net it stable be that in a our contract additional access, time. over Obviously selling relatively did be expect in you'll we we

is do selling that retail Now, Medicare in your of overall, a true-ups fluctuations, QX would as product, some expect you product we But some commercial post because benefit in or price. mix through extent Part you Medicaid comes to make stability see this net the B.

Operator

And Michael the Jefferies. Yee line from our Michael? is next of question from

Michael Yee

I David. for question had an R&D

there get to year. XXX, Of how of quickly going is a lot a data AMG study you this course and made the on later of about great enrolled lot attention comments you we're

first-line One comments of the lung? things I picked up about was on your

comment progresses make about opportunity, first-line? so monotherapy you. strategy that's that a just first-line or go study you Can comment maybe huge how that or Thank and obviously can with maybe just how go that you a where how goes you about a about advances where

Dave Reese

thanks, That option lung such a therapies intended treatment who not other for to provide or therapies. Michael. are patients potential for is eligible Yes to first-line unwilling take

previously have will generate incredibly to the we'll clinical it when enrolling as think data, things drug some We've guidance population. provide as year information response of on valuable course we so a the we to to provide untreated I started may in over the just that, share.

Operator

line Raymond from Chris? is question from next Piper Chris our of Sandler. And

Chris Raymond

San of kind was ago weeks I Bob Francisco. so priorities struck a in M&A on of couple Just

offering you that an bring of Bob interest You and maybe I would pretty But heard of guys a in, the what asset talked you think now. was have area formidable any changing. terms out I in you're about say, augmenting to game and be the that building pipeline renal wording business obviously as is

you renal the parts in for or Thanks. So at game-changing for terms you to And the really of sort what on therapy? reasoning this about then maybe talk that us. least articulating can of two are looking focus

Bob Bradway

we We've commercial franchise in leader you now first. Chris nephrology obviously remind areas, just decades. that of is six one that been so, several our was for a to have area which Yes

have et of We products today patients important a of number we community. nephrologists to to that and needs physicians serve and intend cetera the and in continue for providers

a we've We able own we of have in standpoint. found to efforts in been kinds game changing from discovery want not research to our the that invest that discovery innovation find

opportunities to and is medicines there are we our it make research business for in diseases. patients So we're nephrology that the for look a in not suffering strategy these to development general for look to difference investing when comes discovery now, development right in business big from but going

for I So effect word changer. we'll game innovation size. know that I look large don't the and use

notion I to effect that's innovative But of size reflect was what if the intending I medicines. large did,

to had or the it we in are can again some the look. value, community we'll add there extent, where the with industry we've So investment historical otherwise think because that medicines, we patients’ real of this

Operator

is Robert And of from W. our Baird Brian? Skorney & question next line Brian Co. from

Brian Skorney

just about how actually maintain market been it able - by or far biosimilars last one that price that you and quick X% taken a you quick to in has Onpro like so compared how housekeeping, ones Could Onpro Neulasta price looks decline quarter, of much to on also just loss to share. saw have you impacted talk One two can was discounts breakout maintain been have the share? greater you Thanks.

Bob Bradway

Murdo. ahead go Why for questions Murdo. you those Okay, don't good are

Murdo Gordon

in exited Yes thanks, the Onpro well from a share. Brian. of decline to of up the is majority prefilled continues The terms filgrastim share long-acting share XX% and syringe. hold at of

the had a syringe. see it's a out that discount, Onpro, then on there to We provides would prefilled contract discount have some you more modest but

Operator

And next Suisse. of Evan is line our Seigerman from Credit from Evan? question

Evan Seigerman

some had than potentially business? And biosimilars favored nation to for in be on or said so at clause guys. biosimilars One think the impact factors there across were most one greater index point would multi-billion you, B. Thank I your of you Medicare Part $X to if what an pricing implementation this are franchise. achieve, sales billion gating international for How it's

Bob Bradway

me the I say of biosimilars that But that we start, can we earlier. in. were we expected Murdo, you before the were and since question up that we're good an made part take XX be was for those first heard and you a portfolio invite we undertakings jump of a stab I the these attractive articulated as part growth to opportunity The to your that to company going you the to Murdo. advance of could at team off notion

of excess annualizing of At are fourth we the quarter, the $X end in billion.

to product these launches. approvals the So product item We're on with gating We're we're is on programs start. a and time. simply off budget and good

specifics chance about represent quite to we say the would a to about that earn think well and would biopharmaceutical industry. as it of disruption IPI, enthusiastic remain to we stakeholder adds So be We a these return concerned few obviously groups from IPI general. just our other innovative products would the in the to

add And feel you in specific that if want to Murdo way free we at IPI about to medicines but think in there access landscape. prices, are biosimilar better patients ways to a evolve have anything our affordable ensures system

Murdo Gordon

and for arrival. is summarized would decisions Bob thing and Nothing you have biosimilars, think were my made this I inherited IPI, the say to well on portfolio on I thankful the I'm to that prior only it the

to good we've business U.S. competitive I our being to I launch off a realize forward launch strong in It's Europe we're very look in good this start opportunity. very able to And able think more one, early the products. share to been been and a is in

Operator

of question next Kennen line is MacKay Markets. our And Capital from from Kennen? RBC

Kennen MacKay

you in agree should transformative. between if a you're I and to year totally was of there negotiations. Otezla were expecting about or Enbrel pricing it or for Murdo, both formulary contracting in wondering tailwinds rebating seeing synergies whether end ahead? was any there selling year the I the and We or think little could about access talk Maybe bit

Murdo Gordon

Too footprint. inflammation question, as contracting large between business as continue but quite category. primary expanding a we the possibly potential extension to care biosimilars our even simple through the to specifics, into strategy care fairly Kennen. on because comment have by excited we're frankly strategy, primary for about Thanks we into promotional work promotion coming synergies Yeah things Enbrel, and and Otezla our early

by having clearly, we some And synergies new where those blown the of portfolio augmented new was in then distributors be have is markets. geographic go to Otezla by pieces into Otezla with launched of international full indication areas. then of joining last perhaps And some slated the potential as course our our a markets expansion when we affiliate

about excited those. I'm building So

optimistic hard are we'll Our able specific working upcoming teams feel to that realize more be those to in synergies, and be quarters. I

Operator

from next Umer And ISI. of from line our Evercore Raffat Umer. is question

Umer Raffat

on question two extraordinarily the I I'll but limit my perhaps. things am just specific confused today guidance,

for think as on to you I and with it above First, bear mentioned me interest billion can income. thought that's billion billion just $XXX I $XX a the the minus at second, of $X.X interest you myself about $X.X was through billion OINE an million to Peter line, to $X trying debt if expense, and so X% rate,

to just for trying so to that $X.X to so $XXX number because million thinking wrong, understanding But than that higher understand to was guide you billion, million, is I'm one. or BeiGene. income $XXX billion that's $XXX sounds booking BeiGene's effectively my That's that's $X.X BeiGene $X.X does. what So I billion implied about to only implying billion net am and million $X.X XX% when you're much

you And secondly that all doing Thank perhaps implied also trying is I to understand understand flat $X the on I and year-over-year Otezla, very north billion outside alone better pushes and to just billion so revenues. of was 'XX business the just think what XXXX it mentioned this. there are annual I rate, pulls know being noticed so - $X biosimilars in XQ I run want much.

Bob Bradway

Umer. Okay

I think through questions were three there. go try that, there Let's and

revenue, we to want interest take help the line. and Pete, on Murdo, you can what So two expense then first just and other clarify the said you the clarify

Murdo Gordon

Sure.

base So work that historically that on we number is range portfolio to and outcomes stable that do business yes, we outperform. have of guided hard be done opportunities to year-over-year, to obviously will of a a as our and across there are we've continue

product I early we're through and growth in we that quarter seeing the fourth that the continues with have come team and good Otezla trajectory New and that of Year. - that in seen any without seamless has weeks very and integration say would of performance the interruption strong

we of the products, $X pointed we accelerate very and based it's early two to be at biosimilars, business. as to where you are that quarter on out fourth launch On able annualizing to over expect continue those in billion

Peter Griffith

Umer, fact XXXX, way, at rate publicly Peter results you mentioned average our years, That would for here. total X.X% estimates take XX.X% that available Thanks I for we're to. remarks the to interest that I by consensus plus at maturity talked about XX the BeiGene's in the debt guiding are I what my of the your question. the too.

two, those for our get to through work close you you to should billion when XXXX. $X.X So billion pretty $X.X

Operator

our next Robinson line Robyn of from from question And SunTrust Karnauskas Humphrey. Robin. is

Robyn Karnauskas

half I dead growth like have lack want Neulasta, this you're beat don't holding, your confused I'm growing I of different like products. horse, guess of given too that a lost Onpro's a but to by outlined, slides just bunch you've

you. this most, business one from is struggling sort stable of understand of that's like year-over-year, the not top year going So a you just the with the think growth that more just me thing help to more prevent growing what you it describe, and I'm like that because line. is way you looks what the Thank having

Bob Bradway

Sorry Robyn, piece last your piece question. of repeat the last -

Robyn Karnauskas

stabilizing Sure. way is business business Neulasta, part to in parts be with many you're growing potentially the declining and The basically you're of the seems is that slide describing is your it our performance that Onpro. your is

particular So outlined what painted being why of you what the actually saying think the is grow of preventing there us I more strong. you you've guiding, one you thing, from picture can't growing given quite there beyond what than most is sitting you're business that

Peter Griffith

picture of back pleased comment, So I able We're the the does strong. been last what would look we've with of half year. your achieve, with agree to particularly the quite last business in

expect I expense been of would competitors of terms, total long-acting of the As Neulasta price of there price which the expect worldwide, and we with in additional that the will portfolio in earlier, year. further declines filgrastim mentioned that total for digit single of space category with in would portfolio and net the Neulasta has biosimilar Onpro net net lowered some Onpro price contracted erosion be our the stability inclusive at course, we overall the against

have good not we my hope the in talked we back saw year the the last that but execution it's and into strong a what base business. strong profile, really and number I can year up and products, diverse growth half just Otezla against young portfolio, in continues in this is goes achieve of in a a we drivers that very range Now, throughout the wide of guided have on about growth we revenue call a

Operator

And from Goldman is question Sachs. our of Terence Flynn next Terence. line from

Terence Flynn

a us remarks that your type think terms your, just talked well could later you landscape, what about about year, data? mentioned product of get Thank of program, puts success we Phase as excited you. the remind takes Omecamtiv recently if you is would in X data a of you haven't coming really treatment in here the in obviously you the in lot some change and guys Dave, of and of probability curious guys as this for but kind the it

Dave Reese

is it's we're it's is the function looking a trial mentioned remarks, heart's patients heart measures makes we're to what fairly I'm heart actually happy continue will in definitive advanced be other XXXX-patient sick a going pumping address clinical and for I failure, introduced mortality have improve. that my or a population, ever that contractility to take outcome epidemic, benefit what'll global be cell or where improve the to that. a drug of Terence. of conducting Sure or a heart and acts variety This with action, give in on us first-in-class failure as in excitement omecamtiv, mean, directly to I Dave. mechanism it's the only

profile amount obviously on that that treatment the So medical I there large landscape this of from is train residual Phase need where and trial. unmet X fits depend in a a think changing emerges will

Operator

of Gal next Ronny from Ronny. line question Research. our is And from Bernstein

Ronny Gal

has impact afternoon nice could generally, quick the the where XXXX your was Does will that and housekeeping you then and expect relevance you just wondering one the The on do grant industry. any Medicaid comment us one question. you Good on and block one got congratulations today. that give was it drug announced and I is, to if

modest give David, in the trapping the second, agents. than the I the and GDP KRAS KRAS tumor on me lung view is could your wondering in bound better form tumors your paper targeting those you was the form to if in GDP catering of And suggesting active inactive preventing terms - of resistance

Bob Bradway

and guidance who Good. others I'll on Ronny, CMS are for are released aware, Medicaid still who first the the piece aren't off so call we it. some Well - those earlier let today, knock through me chewing

didn't to us have more industry, specific first see any we'll seem are Ronny for a for go through states was very relevant read be for please. it at you to whether Dave, closely issues, one in instance but me well, our others and but limited ACA you'll business, sure first think of for impact there it opt the it's into those didn't I'm in that I likely that going in that the us, want tackle to concern it XXXX. our be to to as the

Dave Reese

that Yes. Bob. address don't you want I'm sure one, to

for a of interest, paper of course, read so who KRAS Ronny's So, GDP with the that make within month those the inhibition. We last or GXXC signaling that targeting to observations. aren't we the - look suggests out I'll familiar, referring also came paper of would required bound couple form that be for

XXX suggest First, can signaling we achieve AMG I suppressed interval. throughout completely with dosing data and clinically, our that at we own the that doses can appropriate say would a doses

is less quickly It if and oncology is belief used you we've that in very little the resistance. XX a inhibitor that over GXXC years in been understanding completely that learned also paper inhibitor have that my may one potent you target, in thing breed or

of This we're don't as resistance. is of anything the But currently me the we'll generate to see that and sort program So look our I with from would of clinical based on that try AMG at. we're literature say, yet I we've taking. I across data dissuades response XXX feel in of generated the course confident preclinical very and the that profiling tumors to thing signatures approach

Operator

Bansal next our one from Mohit Citi. is Mohit. question And of

Mohit Bansal

a you sort there? it of Otezla psoriasis, have in of net later you. and market is year, of on do anticipate but those baseline data challenge question particular challenges that what about placing in rate is in kind seems this standard navigating a tax mild-to-moderate and that you given generic, market you Thank think how do And care quick a of like that will

Dave Reese

jump me Well, ask start Mohit and I'll Yes. to Murdo let in. then

and there real really disease a to patients will Otezla There therapies oral nearly not right opportunity States control to patients think in those psoriasis, United is approved many mild-to-moderate with in there therapies. therapy, area. in we them alone. million are no are experience topical X that with of So currently is mild-to-moderate The now so available up topical for psoriasis only ultimately thing the

gives that Murdo. size the this a the actually So opportunity sense and you of of of prevalence disease. the

Murdo Gordon

business that a patient Yes described Otezla. use but there the it's thing yes, population it's that there, relief. spot patient as the in largely little Dave a add And and very some is, sweet topical is population a I and is this for methotrexate Mohit, only is gets really largely would

of their when I that is The for have for very, strategy payor to reimbursement and option. say positioning access strategy topical job have other as the and post Otezla our positioning thing their out new a a very nice Otezla colleagues done building pre-biologic

think mild-to-moderate be population for strategy payor I if indication the same that we're in continued. So successful will securing that

for source So, I forward. going feel confident Otezla that we're in good there shape for another of growth

Bob Bradway

So hour Ian, that calls the to let's here, or apologies through got still onto those get several but next queued of we will question. go several the know I we've try were questions top the so up, beyond

Operator

Certainly.

line from from Stanley. Harrison is Morgan question of next Matthew. Our Matthew

Matthew Harrison

what HLE-BiTE that could in activity in have Thanks. I us tumors and you what call, follow on tumors. - the liquid a think to earlier that Maybe I suggesting characterize made internally both statement? that you're you for wanted comment Dave maybe confidence you in the just - that some data that make solid to just gave up seeing

Dave Reese

Yes. Thanks, statement. pick I up someone on that And would Matt. assume that

seeing track. in days of I we're anti-tumor on of victory that yet, right sort is, to activity the reminiscent I'm indication the but encouragement what pharmacodynamic that and activity any of BLINCYTO of declare early not the give us would So ready suggestions say that we're early and are

or have these management format. remarks, half-life adverse that enormous in in to extended noted we've the starting and also experience of HLE starting the to out that an the as T-cell right and to engagers, I some my see of and scheduling events of world I in all we're development is I'd in amount we think bear hints come now learned in appropriate dosing largest point that undoubtedly bispecific of about

to ready we're So not share again, year of some a I'm ready those the as seeing signs data of on. goes encouragement and be but declare victory, we'll to

Operator

Markets. And our line BMO from next from Capital of is Kim Do. question Do

Do Kim

talked primary current would and sales it the on that previously care you How do Aimovig, Just expanding one doing you've about prescribing about your you force? go base. with could

Dave Reese

- sales we doing Thanks, are it Yes. Do. our with current We force.

the into I think some base that now you topiramate and many therapies pathway seeing having we prescribing think class in we're just older trying very category as and effective that in our are given CGRP about XX,XXX a patients coming on treat CGRP I in that and persistency the sufferers about therapies that see therapy fact way oral are it's like I meds persisting to talked on encouraging continue the results, physicians so success. drop there see we are who to on and high low that broaden into the some patients, X,XXX not that older very receiving and care change chronic we're goal and off right and these are I and class, oral think migraine new the are

our to that now. week number efforts, personal the our we're the care applying So selling both right we're all community per digital well is seeing the primary teams we that and looking X,XXX-patient as one in in grow as campaigns right are

So to answer resources that. do is, all the yes, the we required have

Operator

Yaron & is question from of next the Company. from line our And Werber Cowen Yaron?

Yaron Werber

Dave, Murdo. for If just quick a housekeeping you and have mind, don't then a question

final side, before Murdo Omecamtiv, for just us you know look to expectation to like housekeeping about and one let that then now, given it Thank of rate, new beginning But you. that event there XX% grow Repatha, look the DSMB what's now. more On formulation. just the looks can patients at new the have access curious it's you the your - price is

Dave Reese

very Yes of efficacy Yaron, is a interim in high high question. there is a that as occur, bar, bar for I'll -- an the take rule. will the stopping discussed, an statistical so Omecamtiv very very, that terms we've has analysis There previously

our analysis through is that year. the expectation the trial the continue towards will primary end of So the to

Murdo Gordon

of open Repatha reminder, XXX% are And off in to accessing price a for the able physician the how the patients it low-list Repatha And in need commercial paperwork patients can prescribed throughout commercial the without up attestation utilization the majority of been management list original because just is the price prescribing receive condition Yaron, pulled access they Repatha. XXXX, their where we've on we only physicians by and the criteria, December. for majority a so Yes. course market of the

obviously list price. space, because that's the mid-cycle D event Part for the when Medicare in price then us, we low we introduction a of were new And with lowered the

So it's roughly Repatha, affordable of excited accelerating really something an we're as an now about mentioned Medicare to at XX% as have co-pay. access for potential Part D lives was Repatha

to seeing growth we're So going sustained looking forward forward.

I and to all being about have in sales able should Our more they way along. everybody pretty been with quite our teams Dallas are ready is treated patients treat and forces just frankly excited the was

Operator

line Leerink. question is Geoffrey next from SVB from of our Porges And Geoffrey.

Geoffrey Porges

for Murdo. then one housekeeping quick A and

and already, think is can First, become Forteo's most obviously - brand is Dave annualizing what impressed already? about I the number, I'm us could reception CX the biosimilar program of of you Could sort us bit million you which just the a exclusivity, it whether Murdo talk better for Thanks. its update Murdo, seeing still and given you it a $XXX is, losing think with little this you're that really become Evenity receiving you're where can give an anticipated. then active on you're than Forteo-like

Dave Reese

take Soliris expect enrolling XXX and to or the first I'll you can the the trial of ABP Jeff, biosimilar, part we so provide as is to that we'll X see Phase when conclusion to guidance of data. come Yes. relating that actively question

Murdo Gordon

thanks Geoffrey, on for of And Evenity. Yes. the question

been has two reflective pleased with are short nothing Japan markets, has partners, reception with The launch it's primarily. and success excellent. a physician out our been there of UCB, I and trajectory Japanese U.S. Evenity, We really on the launch think resounding Astellas of

product We younger trajectory to really same nonetheless and the launch that's be U.S., in one I positioned for risk done accepting thing where most post-fracture physicians has the the little exceeded patients that and think seems but in we've the the our gone that as expectations well a own U.S., well. are and benefit our high-risk off the equation is it's

J got recently permanent our and in the well. base U.S. code just opening We as prescriber the that's up

and be successful UCB course with our us thanks from will that of will across have a there. commercializing So Europe, the we I some franchise help hands with do to the on EMA think very approval

So overall, a - remains as be as whether to will it that be Forteo seen. big

on you duration, a the as product are remind in I it's high take multiple but the the years, less exciting. clearly low-end end it's much XX% of We it's than a you not XX% that competitors new slightly for duration will XX-month XX-month - on the so acquisition as patient category, expensive is our for

Operator

And our Alethia from next of is question line Fitzgerald. Young from Cantor Alethia?

Alethia Young

of been doing drug that's has I spite in another guess well that of quite part Sensipar. been

you demand XX obviously us months. contracting XX had next maybe think should unit how expect some of growth. it. months continued Thanks. prior about we for about probably parts to talk you just the can frame help the of kind know I maybe So over But

Dave Reese

the performance thanks, Parsabiv for rate little, a was year but the it's broad There Alethia. too of is Parsabiv fantastic. really into a may outcomes Yes, it. to growth There and in last call. range a patients, number are that early going into is The are slow Parsabiv of from reimbursement who benefiting change coming of XXXX

Bob Bradway

then more wrap think try calls we'll we've up. them I and got get Ian, Okay, we two to

Operator

well. Very

Salim next Our from Securities. is Mizuho Salim? question line Syed of from

Salim Syed

the in on the flows you or at to recent looking are and the for top the clarity enrolled SGLTX you're competing and the Omecamtiv, getting that I of space be then talking landscape trial. believe Thank when And some of be presume me to on guess there commentary mentioned on actually in what for on about if one envisioning this patients any head specifically and was the Omecamtiv you Just changing some David, from the provide, I you. on you will be is data. SGLTXs I

Dave Reese

the Salim. patients probably less was to those sense reference Yes, were the particular, population. in I treated thanks SGLTXs making that so Yes, somewhat studies sick our is in a

lack intended drug-drug seen now and differentiation as interactions to may we then of It an be So a action. along of the have mechanism we've therapies. all given that point in intended add-on Omecamtiv the is with our that of be to other

in at SGLTXs course, number who X Phase Of study. in we trial, the are things the look as of such will receiving patients,

Bob Bradway

last Okay, question. let's the get

Operator

And our JPMorgan. final Kasimov from Cory? question line of is from Cory

Unidentified Analyst

into apologize Thanks fitting or this your the this with this we what the Hi, for in. for existing if and wondering Otezla. Cory. on concerns. just any competitive double-digit you going Does label Gavin but is label a is expansion on comment are assumptions I answered for are growth or this, us imply

Bob Bradway

I we just think addressed reiterate that. what Gavin, But we've that. we is for you behind think And

Dave Reese

Yes.

we would assuming new right rate we secure we're where patients a historical in forward. that sourcing So now. We're growth indications double-digit and using are going also additional our for assumption

think clear. pretty I that's So

Bob Bradway

Thanks everyone. patience. for your Okay,

year to a little cusp us, past of of be we me just and where growth. revenue let Sorry. now about managing hour, the the we good by going that a We ended we're conclude period was allotted always think through transition in but saying a we feel for what XXXX new on bit went product

as to this towards well of particularly forward that And So second the forward to data half important is we look look we that. expected clinical year.

to I take on didn't serve a to the remiss just So staff well to world, mission I'd patients. moment if thank our day the deliver who continue so to as every work Amgen be hard around

the them. to to of in quarter. So we thank after forward you chance you talk all April to me to first let And look

Peter Griffith

everybody Thanks participation. Bob. Thanks for your

for and the cover, you IR team course would hours. questions the good have myself, day. you a like rest If several to other of will of any around be Have

Operator

We Amgen's Ladies thank quarter and results call. gentlemen, financial for you this does conference conclude fourth us. XXXX joining

now disconnect. You may

Amgen (AMGN) 30 Jan 202019 Q4 Earnings call transcript